Skip to main navigation menu Skip to main content Skip to site footer

Prevalence of dynapenia (decreased strength), sarcopenia and possible biomarkers in cardiac rehabilitation

Prevalencia de dinapenia (disminución de la fuerza), sarcopenia y posibles biomarcadores en rehabilitación cardíaca




Section
Research Article

How to Cite
Medina Victoria, D. A., Laverde , L. A. ., Alviz Conde, L. K., & Galvis, J. C. (2020). Prevalence of dynapenia (decreased strength), sarcopenia and possible biomarkers in cardiac rehabilitation. Journal of Medicine and Surgery Repertoire, 30(2), 142-149. https://doi.org/10.31260/RepertMedCir.01217372.989

Dimensions
PlumX
license

   

Daniel Alexander Medina Victoria
    Lina Alexandra Laverde
      Luz Karime Alviz Conde
        Juan Carlos Galvis

          Introduction: the relationship between dynapenia and sarcopenia results in an additional increment in the risk of morbidity and mortality in the general population, with a progressive age-associated increase. From the age of 30, exercise capacity, quality of life and mood are affected due to decreased muscle mass and strength. Objective: to determine the prevalence of dynapenia and sarcopenia in patients in cardiac rehabilitation in a Colombian hospital by measuring their muscle strength and biochemical markers. Methods: a cross-sectional study of patients over 40, in cardiac rehabilitation, attending follow-up visits at least once a week. Muscle strength was measured with a handheld dynamometer, muscle mass with bipolar impedance and walking speed with the 6-meter walking test. Growth hormone (GH), testosterone, somatomedin IGF-1 levels and control measurements were taken. Results: decrease in muscle strength was prevalent in men (n=15, 19.4%; women n=5, 10%). The prevalence of dynapenia was 15.7% and of sarcopenia 0%. The results obtained were GH 0.27 (0.08-1.18), testosterone 5.9 (0.3-8.5), IGF-1 126 (95.5-169) cortisol 13.9 (11.2-18.4). The most frequent pathological conditions of patients in the program were myocardial infarction, angioplasty and stent implantation. Conclusions: the prevalence of dynapenia was 15.7%. No difference in biochemical markers was found in patients with or without dynapenia.


          Article visits 2334 | PDF visits 1640


          Downloads

          Download data is not yet available.
          1. Ricci WM, Brandt A, McAndrew C, Gardner MJ. Factors affecting delay to surgery and length of stay for patients with hip fracture. J Orthop Trauma. 2015;29(3):e109-14. doi: https://doi.org/10.1097/BOT.0000000000000221
          2. Borghans I, Kleefstra SM, Kool RB, Westert GP. Is the length of stay in hospital correlated with patient satisfaction?. Int J Qual Heal Care. 2012;24(5):443-51. doi: https://doi.org/10.1093/intqhc/mzs037
          3. Clark BC, Manini TM. Sarcopenia =/= dynapenia. The journals of gerontology Series A, Biological sciences and medical sciences. 2008;63(8):829-34. doi: https://doi.org/10.1093/gerona/63.8.829
          4. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412-23. doi: https://doi.org/10.1093/ageing/afq034
          5. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. doi: https://doi.org/10.1093/ageing/afy169
          6. Ali S, Garcia JM. Sarcopenia, cachexia and aging: diagnosis, mechanisms and therapeutic options - a mini-review. Gerontology. 2014;60(4):294-305. doi: 10.1159/000356760
          7. Harada H, Kai H, Shibata R, Niiyama H, Nishiyama Y, Murohara T, et al. New diagnostic index for sarcopenia in patients with cardiovascular diseases. PloS one. 2017;12(5):e0178123. doi: doi: https://doi.org/10.1371/journal.pone.0178123.t001
          8. Han P, Yu H, Ma Y, Kang L, Fu L, Jia L, et al. The increased risk of sarcopenia in patients with cardiovascular risk factors in Suburb-Dwelling older Chinese using the AWGS definition. Sci Rep. 2017;7(1):9592. doi: http://dx.doi.org/10.1038/s41598-017-08488-8
          9. Tanaka S, Kamiya K, Hamazaki N, Matsuzawa R, Nozaki K, Maekawa E, et al. Utility of SARC-F for Assessing Physical Function in Elderly Patients With Cardiovascular Disease. J Am Med Dir Assoc. 2017;18(2):176-81. doi: https://doi.org/10.1016/j.jamda.2016.10.019
          10. Chin SO, Rhee SY, Chon S, Hwang YC, Jeong IK, Oh S, et al. Sarcopenia is independently associated with cardiovascular disease in older Korean adults: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2009. PloS one. 2013;8(3):e60119. doi: https://doi.org/10.1371/journal.pone.0060119
          11. Bonnefoy M, Berrut G, Lesourd B, Ferry M, Gilbert T, Guerin O, et al. Frailty and nutrition: searching for evidence. J Nutr Heal Aging. 2015;19(3):250-7. doi: https://doi.org/10.1007/s12603-014-0568-3
          12. Heymsfield SB, Gonzalez MC, Lu J, Jia G, Zheng J. Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia. Proc Nutr Soc. 2015;74(4):355-66. doi: https://doi.org/10.1017/S0029665115000129
          13. Edwards MH, Buehring B. Novel Approaches to the Diagnosis of Sarcopenia. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry. 2015;18(4):472-7. Doi: http://dx.doi.org/10.1016/j.jocd.2015.04.010
          14. Keller K. Sarcopenia. Wien Med Wochenschr. 2019;169(7-8):157-72. doi: https://doi.org/10.1007/s10354-018-0618-2
          15. Shin MJ, Jeon YK, Kim IJ. Testosterone and Sarcopenia. The world journal of men's health. 2018;36(3):192-8. doi: https://doi.org/10.5534/wjmh.180001
          16. Baumgartner RN, Waters DL, Gallagher D, Morley JE, Garry PJ. Predictors of skeletal muscle mass in elderly men and women. Mech Ageing Dev. 1999;107(2):123-36. doi: https://doi.org/10.1016/s0047-6374(98)00130-4
          17. Morley JE, Baumgartner RN, Roubenoff R, Mayer J, Nair KS. Sarcopenia. The Journal of laboratory and clinical medicine. 2001;137(4):231-43. doi: https://doi.org/10.1067/mlc.2001.113504
          18. Burton LA, Sumukadas D. Optimal management of sarcopenia. Clin Interv Aging. 2010;5:217-28. doi: https://doi.org/10.2147/cia.s11473
          19. Lapauw B, Goemaere S, Zmierczak H, Van Pottelbergh I, Mahmoud A, Taes Y, et al. The decline of serum testosterone levels in community-dwelling men over 70 years of age: descriptive data and predictors of longitudinal changes. Eur J Endocrinol. 2008;159(4):459-68. doi: https://doi.org/10.1530/EJE-07-0873
          20. Schopfer DW, Forman DE. Cardiac Rehabilitation in Older Adults. The Can J Cardiol. 2016;32(9):1088-96. doi: http://dx.doi.org/10.1016/j.cjca.2016.03.003
          21. Harada H, Kai H, Niiyama H, Nishiyama Y, Katoh A, Yoshida N, et al. Effectiveness of Cardiac Rehabilitation for Prevention and Treatment of Sarcopenia in Patients with Cardiovascular Disease - A Retrospective Cross-Sectional Analysis. J Nutr Heal Aging. 2017;21(4):449-56. doi: http://dx.doi.org/10.1007/s12603-016-0743-9
          22. Falcon LJ, Harris-Love MO. Sarcopenia and the New ICD-10-CM Code: Screening, Staging, and Diagnosis Considerations. Fed Pract. 2017;34(7):24-32.
          23. Patino-Hernandez D, David-Pardo DG, Borda MG, Perez-Zepeda MU, Cano-Gutierrez C. Association of Fatigue With Sarcopenia and its Elements: A Secondary Analysis of SABE-Bogota. Gerontol Geriatr Med. 2017;3:2333721417703734. doi: http://dx.doi.org/10.1177/2333721417703734
          24. Ferrini RL, Barrett-Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol. 1998;147(8):750-4. doi: http://dx.doi.org/10.1093/oxfordjournals.aje.a009519
          25. Curcio F, Ferro G, Basile C, Liguori I, Parrella P, Pirozzi F, et al. Biomarkers in sarcopenia: A multifactorial approach. Exp Gerontol. 2016;85:1-8. doi: http://dx.doi.org/10.1016/j.exger.2016.09.007
          26. Cruz-Jentoft AJ, Landi F, Topinkova E, Michel JP. Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care. 2010;13(1):1-7. doi: http://dx.doi.org/10.1097/MCO.0b013e328333c1c1
          27. Taekema DG, Ling CH, Blauw GJ, Meskers CG, Westendorp RG, de Craen AJ, et al. Circulating levels of IGF1 are associated with muscle strength in middle-aged- and oldest-old women. Eur J Endocrinol. 2011;164(2):189-96. doi: http://dx.doi.org/10.1530/EJE-10-0703
          28. Diaz Munoz GA, Cardenas Zuluaga DM, Mesa Jimenez A. [Consistency of Mini Nutritional Assessment to Identify Sarcopenia in Older Adults in Nursing Homes in Bogota, Colombia]. Nutr Hosp. 2015;32(1):270-4. Consistencia del mini nutritional assessment para identificar la sarcopenia en adultos mayores de hogares geriatricos de Bogotá, Colombia. doi: http://dx.doi.org/10.3305/nh.2015.32.1.8816
          29. Krokstad S, Ding D, Grunseit AC, Sund ER, Holmen TL, Rangul V, et al. Multiple lifestyle behaviours and mortality, findings from a large population-based Norwegian cohort study - The HUNT Study. BMC public health. 2017;17(1):58. doi: http://dx.doi.org/10.1186/s12889-016-3993-x
          30. Farhud DD. Impact of Lifestyle on Health. Iran J Public Health. 2015;44(11):1442-4.
          31. Abeytua Jiménez M, Castillo Martín JI, Martínez Castellanos T, Fernández González A, Ortega MÁ, Davalillo C, et al. Valoración del test de los seis minutos marcha y fracción de eyección del ventrículo izquierdo en pacientes que realizan programa de rehabilitación cardiaca. Rev Esp Cardiol. 2011;64 (Supl 3):375.
          Sistema OJS 3.4.0.5 - Metabiblioteca |